---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-014489"
form_type: "8-K/A"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2022-04-14T23:59:59+00:00"
generated_at: "2026-06-26T07:19:41.175582+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# FDA grants orphan drug designation to aTyr Pharma's efzofitimod for systemic sclerosis

## Summary
- FDA granted orphan drug designation for efzofitimod to treat systemic sclerosis (scleroderma) on April 12, 2022.
- Orphan designation may provide 7-year market exclusivity, tax credits, and waiver of FDA fees.
- Efzofitimod is aTyr's lead therapeutic candidate; this designation supports its development program.

## SEC filing metadata
- accession: 0001564590-22-014489
- form_type: 8-K/A
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2022-04-14T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000156459022014489/0001564590-22-014489-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000156459022014489/life-8ka_20220412.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-014489
- JSON: https://secwatch.observer/filing/0001564590-22-014489.json
- Plain text: https://secwatch.observer/filing/0001564590-22-014489.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.